Heron Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2015. Financial statements are unaudited and prepared under U.S. GAAP. Heron is a pre-commercial biotechnology company developing four product candidates for cancer and pain indications: SUSTOL, HTX-019, HTX-011 and HTX-003.
Business Context and Period Highlights
- SUSTOL’s NDA was resubmitted to the FDA in July 2015 and had a PDUFA goal date of January 17, 2016. SUSTOL was not yet approved or generating product revenue.
- The Phase 3 MAGIC study for SUSTOL achieved its primary endpoint for delayed chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy patients.
- HTX-011 reported positive top-line Phase 2 bunionectomy results in September 2015. The company planned to expand an ongoing inguinal hernia study and initiate additional Phase 2 studies.
- Heron planned to file an NDA for HTX-019 under the 505(b)(2) pathway in the second half of 2016.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $14.2 million, versus $14.7 million | $44.9 million, versus $40.6 million |
| General and administrative expense | $8.3 million, versus $4.2 million | $20.9 million, versus $14.4 million |
| Total operating expenses | $22.5 million, versus $19.0 million | $65.9 million, versus $55.1 million |
| Net loss | $22.7 million, versus $19.2 million | $66.3 million, versus $55.7 million |
| Net loss per share | $0.63, versus $0.66 | $2.07, versus $2.17 |
| Net cash used in operating activities | Not separately provided | $55.4 million, versus $47.4 million |
| Stock-based compensation | $2.8 million, versus $1.8 million | $8.5 million, versus $5.8 million |
Margins and profitability: Gross margin and operating margin were not meaningful because the company reported no product revenue. Heron remained loss-making and expected substantial future losses.
Cash, Liquidity and Debt
- Cash and cash equivalents were $153.0 million at September 30, 2015, compared with $72.7 million at December 31, 2014.
- Cash increased by $80.3 million during the first nine months, primarily from $128.2 million of net proceeds from a June 2015 common-stock offering and $7.9 million from stock-option exercises.
- Management believed existing cash and working capital were sufficient to fund operations through 2016 under current plans, including SUSTOL commercialization preparation and ongoing clinical programs.
- Convertible notes had a carrying value of $2.1 million and aggregate principal of $5.6 million. The notes bear 6% interest, are secured by substantially all company assets, and may be required to be prepaid at the holders’ option.
- Conversion of the notes could result in issuance of approximately 7.0 million shares. The company was in compliance with the notes’ covenants at September 30, 2015.
- Operating lease obligations totaled $1.4 million, including $1.1 million due within one year. The company reported no off-balance-sheet arrangements.
Material Changes Versus Prior Comparable Period
- Nine-month research and development expense increased 11% to $44.9 million, mainly because of higher HTX-011 and HTX-019 clinical, manufacturing and development costs. SUSTOL costs declined after completion of its Phase 3 study in May 2015.
- Nine-month general and administrative expense increased 45% to $20.9 million, primarily due to preparation for a potential SUSTOL commercial launch and higher stock-based compensation.
- Nine-month net loss increased 19% to $66.3 million, while net loss per share improved to $2.07 from $2.17 because of a higher share count.
- Operating cash use increased to $55.4 million from $47.4 million.
- Equity financing materially strengthened liquidity but increased the outstanding share base and potential dilution.
Guidance, Outlook, Risks and Unusual Items
- Management did not provide revenue or earnings guidance. Its liquidity outlook assumes current operating plans and does not cover significant expansion, acquisitions or weaker-than-expected SUSTOL performance.
- Additional capital may be required if SUSTOL is not approved, commercial uptake is below expectations, development activities expand, or the company pursues acquisitions or other programs. Future equity financing could dilute existing stockholders.
- Key near-term catalysts included the FDA decision on SUSTOL by January 17, 2016, HTX-011 clinical progress and planned HTX-019 regulatory preparation.
- Material risks include another FDA complete response letter, limitations on SUSTOL’s approved label, manufacturing and supplier deficiencies, clinical-trial delays or failures, dependence on contract research organizations and manufacturers, reimbursement and competitive pressures, intellectual-property challenges and the inability to establish commercial sales capabilities.
- The company remains substantially dependent on SUSTOL and has no current means of generating material operating cash flow.
- Stock-based compensation was a significant non-cash expense, and approximately $31.2 million of unrecognized compensation cost remained at September 30, 2015.
- A gain of approximately $0.1 million from the sale of property and equipment and approximately $0.1 million of interest income reduced nine-month other expense.
- No legal proceedings, defaults upon senior securities or material control deficiencies were reported.
Important Facts for Investors to Verify
- FDA’s action on the resubmitted SUSTOL NDA and the scope of any approved indication.
- Resolution of prior FDA manufacturing concerns and readiness of third-party manufacturers for commercial-scale production.
- Cash-burn trends, the timing of potential additional financing and dilution from future equity issuance or note conversion.
- Enrollment, efficacy, safety and timing of results for HTX-011 and HTX-019 clinical programs.
- Commercial-launch spending, development of sales and marketing infrastructure, and potential reimbursement and competitive dynamics.
- Potential dilution from approximately 7.0 million shares underlying convertible notes, outstanding options and warrants.